相似文献
1
Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users.
J Epidemiol Community Health. 1999 Jul;53(7):434-5. doi: 10.1136/jech.53.7.434.
2
Hepatitis C infection among injecting drug users attending the National Drug Treatment Centre.
Ir J Med Sci. 1995 Oct-Dec;164(4):267-8. doi: 10.1007/BF02967199.
3
Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran.
Int J Drug Policy. 2007 Oct;18(5):359-63. doi: 10.1016/j.drugpo.2007.02.007. Epub 2007 Apr 30.
4
Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Harm Reduct J. 2015 Oct 16;12:22. doi: 10.1186/s12954-015-0056-z.
5
Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Eur J Gen Pract. 2007;13(1):5-12. doi: 10.1080/14017430601049365.
6
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.
BMJ. 1998 Aug 15;317(7156):433-7. doi: 10.1136/bmj.317.7156.433.
7
European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability.
Euro Surveill. 2008 May 22;13(21):18884. doi: 10.2807/ese.13.21.18884-en.
8
High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
J Epidemiol Community Health. 2015 Jun;69(6):599-603. doi: 10.1136/jech-2014-205070. Epub 2015 Apr 13.
9
Blood-borne infections in Dublin's opiate users.
Ir J Med Sci. 2001 Jan-Mar;170(1):32-4. doi: 10.1007/BF03167717.
10
Hepatitis C infection among injecting drug users in Scotland: stemming the flow.
Scott Med J. 2000 Oct;45(5):131-2. doi: 10.1177/003693300004500501.
引用本文的文献
1
Hepatitis C virus infection in Irish drug users and prisoners - a scoping review.
BMC Infect Dis. 2019 Aug 8;19(1):702. doi: 10.1186/s12879-019-4218-6.
2
Incidence of hepatitis C among people who inject drugs in Ireland.
Hepatol Med Policy. 2017 Jan 26;2:7. doi: 10.1186/s41124-017-0024-1. eCollection 2017.
3
Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months.
BMC Pediatr. 2018 May 4;18(1):151. doi: 10.1186/s12887-018-1137-4.
4
Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review.
AIDS Behav. 2013 Nov;17(9):2878-92. doi: 10.1007/s10461-013-0593-y.
5
Analysis of duration of risk behaviour for key populations: a literature review.
Sex Transm Infect. 2012 Dec;88 Suppl 2(Suppl_2):i24-32. doi: 10.1136/sextrans-2012-050647.
6
A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users.
Harm Reduct J. 2006 Sep 6;3:27. doi: 10.1186/1477-7517-3-27.
7
Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunisation uptake.
Ir J Med Sci. 2005 Apr-Jun;174(2):14-20. doi: 10.1007/BF03169123.
8
Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area.
Ir J Med Sci. 2005 Jan-Mar;174(1):37-41. doi: 10.1007/BF03168517.
9
Blood-borne infections in Dublin's opiate users.
Ir J Med Sci. 2001 Jan-Mar;170(1):32-4. doi: 10.1007/BF03167717.
10
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey.
BMJ. 2000 Jul 8;321(7253):78-82. doi: 10.1136/bmj.321.7253.78.
本文引用的文献
1
Once more unto the breach: controlling hepatitis C in injecting drug users.
Addiction. 1996 Feb;91(2):181-4. doi: 10.1111/j.1360-0443.1996.tb03174.x.
2
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.
Am J Public Health. 1996 May;86(5):655-61. doi: 10.2105/ajph.86.5.655.
3
Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years.
BMJ. 1994 Aug 6;309(6951):369-72. doi: 10.1136/bmj.309.6951.369.
4
Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993.
AIDS. 1995 May;9(5):493-501.
5
Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.
Am J Public Health. 1995 Nov;85(11):1531-7. doi: 10.2105/ajph.85.11.1531.
Zotero 插件